Document Type : Original Article(s)
- Saeed Alipour-Parsa 1
- Habib Haybar 2
- Mohammad Hasan Namazi 3
- Morteza Safi 3
- Isa Khaheshi 4
- Mehdi Memaryan 5
- Amir Mohammad Eghbalnejad-Mofrad 6
1 Associate Professor, Cardiovascular Research Center AND Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Assistant Professor Cardiovascular Research Center AND Department of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Professor, Cardiovascular Research Center AND Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Assistant Professor, Cardiovascular Research Center AND Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Cardiologist, Cardiovascular Research Center AND Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 Student of Medicine, Student Research Committee, Department of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
BACKGROUND: Inflammation has an important role in the development and progression of atherosclerosis, and acute phase proteins such as pentraxin-3 (PTX3) can be deployed in determining the prognosis of coronary artery disease (CAD). So the purpose of this paper was to evaluate the PTX3 level and its related factors in patients undergoing primary percutaneous coronary intervention (PCI). METHODS: In this cross-sectional study, the PTX3 levels were determined for 100 patients with ST-elevation myocardial infarction referred to the Modarres Hospital, Tehran, Iran. Checklist included demographic data [age, gender, history of myocardial infarction (MI)] and characteristics of heart disease (type of MI, culprit, and pre-dilation). PTX3 was measured for all patients before PCI. RESULTS: In this study, the mean age of the participants was 58.7 (11.4). Global registry of acute coronary events (GRACE) score was higher in the group with abnormal PTX3 levels (P = 0.008). The number of the involved vessels (P = 0.005), MI type (P = 0.05), and the need for PCI all had a significant relation with abnormal PTX3 levels. The increased levels of PTX3 received higher Killip class, lower ejection fraction, and higher GRACE score. The group with abnormal PTX3 had a significant difference in platelet counts (P = 0.018) in comparison with the group with normal level of PTX3. CONCLUSION: Currently, the biomarkers are highly important in the field of cardiovascular diseases. The diagnostic and prognostic importance of PTX3 as a new marker has been underscored in recent studies. Differentiating between high-risk patients with acute cardiac infarction and low-risk ones through their clinical signs is difficult.
- Liuzzo G. Atherosclerosis: An inflammatory disease. Rays 2001; 26(4): 221-30.
- Maseri A, Fuster V. Is there a vulnerable plaque? Circulation 2003; 107(16): 2068-71.
- Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-66.
- Maugeri N, Rovere-Querini P, Slavich M, Coppi G, Doni A, Bottazzi B, et al. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol 2011; 187(2): 970-9.
- Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27(1): 161-7.
- Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008; 215(1): 48-55.
- Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110(16): 2349-54.
- Knoflach M, Kiechl S, Mantovani A, Cuccovillo I, Bottazzi B, Xu Q, et al. Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies. PLoS One 2012; 7(2): e31474.
- Wang Z, Sato A, Akiyama D, Kimura T, Tajiri K, Hoshi T, et al. Clinical value of plasma pentraxin 3 levels for predicting cardiac troponin elevation after percutaneous coronary intervention. Life Sci 2014; 95(1): 40-4.
- Salio M, Chimenti S, De Angelis N, Molla F, Maina V, Nebuloni M, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008; 117(8): 1055-64.
- Lee DH, Jeon HK, You JH, Park MY, Lee SJ, Kim SS, et al. Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J 2010; 40(8): 370-6.
- Namazi MH, Saadat H, Safi M, Vakili H, Alipourparsa S, Bozorgmanesh M, et al. Pentraxin 3 is highly specific for predicting anatomical complexity of coronary artery stenosis as determined by the synergy between percutaneous coronary intervention with taxus and cardiac surgery score. Korean Circ J 2014; 44(4): 220-6.
- Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, Buyukkaya S, et al. Serum pentraxin 3 levels are associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris. J Investig Med 2013; 61(2): 278-85.
- Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008; 155(1): 75-81.
- Kurtul A, Yarlioglues M, Murat SN, Ergun G, Duran M, Kasapkara HA, et al. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol 2014; 114(3): 342-7.
- Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis 2012; 34(3): 326-34.
- Balta S, Ozturk C. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets 2015; 26(7): 680-1.
- Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26(2): 135-40.
- Duygu H, Turkoglu C, Kirilmaz B, Turk U. Effect of mean platelet volume on postintervention coronary blood flow in patients with chronic stable angina pectoris. J Invasive Cardiol 2008; 20(3): 120-4.